遗忘 发表于 2025-3-23 10:46:35
http://reply.papertrans.cn/59/5891/589072/589072_11.pngAmbiguous 发表于 2025-3-23 17:21:21
http://reply.papertrans.cn/59/5891/589072/589072_12.pngAtrium 发表于 2025-3-23 20:34:31
http://reply.papertrans.cn/59/5891/589072/589072_13.pngkeloid 发表于 2025-3-24 01:07:40
http://reply.papertrans.cn/59/5891/589072/589072_14.png努力赶上 发表于 2025-3-24 03:05:53
Immune Therapy: What Can We Learn From Acquired Resistance?,sponse to these agents can be durable, but most patients will go on to develop resistance after initial tumor regression or prolonged disease stability. In patients with ‘acquired oligo-resistance,’ in whom progression is limited to two or less disease sites, local therapy may be an effective manage无力更进 发表于 2025-3-24 10:16:21
Management of Brain Metastases, brain metastases is increasing. Lung cancer is the most frequent origin of metastases to the brain, and this diagnosis is associated with significant morbidity as well as decreased quality of life and a worse prognosis. The treatment for brain metastases in NSCLC has historically been local therapyType-1-Diabetes 发表于 2025-3-24 14:17:50
http://reply.papertrans.cn/59/5891/589072/589072_17.pngNeutral-Spine 发表于 2025-3-24 16:14:21
http://reply.papertrans.cn/59/5891/589072/589072_18.pngCOM 发表于 2025-3-24 21:52:35
Small Cell Lung Cancer: Biology Advances,une checkpoint inhibitors have been approved for use in combination with etoposide plus a platinum agent as initial therapy for patients extensive stage SCLC; with the triplet regimen, the median overall survival is approximately 12 months. Over the past 4 years, several agents, including immune che使混合 发表于 2025-3-24 23:51:13
http://reply.papertrans.cn/59/5891/589072/589072_20.png